---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-120289"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:05:31.688324+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corbus presents pre-clinical data for obesity drug CRB-913; Phase 1 start Q1 2025

## Summary
- CRB-913 showed 15-fold lower brain levels vs monlunabant in mice; plasma-to-brain ratio 10x better than monlunabant.
- Weight loss up to 38% in DIO mice at 80 mg/kg/day over 28 days; no plateau at doses up to 80 mg/kg/day.
- Switching from semaglutide to CRB-913 maintained weight loss post-withdrawal, with doubling of fat reduction vs semaglutide alone.
- Human-equivalent doses range from 30 mg/day to 450 mg/day based on allometric scaling.
- IND-enabling studies ongoing; first patient in Phase 1 expected in Q1 2025.

## SEC filing metadata
- accession: 0000950170-24-120289
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017024120289/0000950170-24-120289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017024120289/crbp-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-120289
- JSON: https://secwatch.observer/filing/0000950170-24-120289.json
- Plain text: https://secwatch.observer/filing/0000950170-24-120289.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.